Testing directly on viable human tissue, we also analyse data at the single cell level. In the landmark EXALT-1 clinical study, our platform demonstrated for the first time that functional precision-oncology can improve patient outcome in a prospective interventional trial. Find out more on this page.

First integrated system to demonstrate improved clinical outcomes in oncology using live patient tissue and the power of AI

25359545_Ball_animation.mp4

Interrogating activities directly in viable human tissue samples allows us to generate deep, clinically relevant insights into which molecules will deliver the most treatment benefit. 

Exploring response at single cell resolution allows us to even distinguish on-target from off-target response in complex tissues 

Powered by AI, for the benefit of the patient, we are pioneering new approaches in precision medicine, demonstrating for the first time that functional precision-oncology can improve patient outcome in a prospective interventional trial.

In the landmark study, it was demonstrated for the first time that our functional precision-oncology platform can improve patient outcome in a prospective interventional trial.

Pioneering work by our team has delivered a platform able to anticipate the effectiveness of cancer treatments in the clinic,  using AI to analyse the activity of drugs in live patient samples, at single-cell resolution.  

EXALT-1 is the ﬁrst-ever prospective interventional study of its kind. Predictions made by the platform proposed which therapy would be most effective for late stage haematological cancer patients based on testing drug responses ex vivo in their own tissue samples.   

removePaddingTop removePaddingBottom title36px

EXALT-1 demonstrated real-world patient selection capabilities by achieving a 55% response rate and statistically significant improvement in progression free survival over the prior line of therapy for patients that were treated following the platform’s recommendation. 

In a post hoc analysis, patients receiving therapy recommended by the platform showed significantly improved outcomes compared to their prior treatments, whereas patients who received treatments other than the platform recommended therapy showed worse outcomes.

<div style="text-align:center;">
<div><img src= "https://images.prismic.io/exscientia/424dc60b-9fcc-4976-8e6b-6df90d05028b_Cancer-Discovery-logo.jpg?auto=compress,format" style="max-width: 400px; margin-top: 3rem;" alt="Cancer Discovery"></div>

<a class="btn ctaBannerLink" href="https://cancerdiscovery.aacrjournals.org/content/early/2021/09/29/2159-8290.CD-21-0538" style="margin-top: 2rem;">Learn more</a></div>

Precision Medicine

First integrated system to demonstrate improved clinical outcomes in oncology using live patient tissue and the power of AI

Human Tissue

Single Cell

AI Analysis

EXALT-1: Clinical Trial

EXALT-1

Progression Free Survival